These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 9764797)

  • 61. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group.
    Savès M; Raffi F; Clevenbergh P; Marchou B; Waldner-Combernoux A; Morlat P; Le Moing V; Rivière C; Chêne G; Leport C
    Antimicrob Agents Chemother; 2000 Dec; 44(12):3451-5. PubMed ID: 11083658
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Evaluating supervised HAART in late-stage HIV among drug users: a preliminary report.
    Greenberg B; Berkman A; Thomas R; Hoos D; Finkelstein R; Astemborski J; Vlahov D
    J Urban Health; 1999 Dec; 76(4):468-80. PubMed ID: 10609596
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A risk-benefit assessment of HIV protease inhibitors.
    Moyle GJ; Gazzard BG
    Drug Saf; 1999 Apr; 20(4):299-321. PubMed ID: 10230580
    [TBL] [Abstract][Full Text] [Related]  

  • 64. HIV and hepatitis C virus co-infection.
    Sulkowski M
    Hopkins HIV Rep; 1998 Nov; 10(6):8, 12. PubMed ID: 11366132
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
    Pineda JA; Santos J; Rivero A; Abdel-Kader L; Palacios R; Camacho A; Lozano F; Macías J;
    J Antimicrob Chemother; 2008 Apr; 61(4):925-32. PubMed ID: 18276600
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Type 2 diabetes in association with HIV-1 protease inhibitors in HIV-infected patients.
    Chronister CL; Gurwood AS
    J Am Optom Assoc; 1998 Nov; 69(11):695-8. PubMed ID: 9844321
    [No Abstract]   [Full Text] [Related]  

  • 68. Acute hepatitis in HIV-infected patients during ritonavir treatment.
    Arribas JR; Ibáñez C; Ruiz-Antoran B; Peña JM; Esteban-Calvo C; Frías J; Vázquez JJ; González-García JJ
    AIDS; 1998 Sep; 12(13):1722-4. PubMed ID: 9764797
    [No Abstract]   [Full Text] [Related]  

  • 69.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 70.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 71.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 72.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 73.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.